News & Events

Filter Year   Keywords   > Submit

Page 2

ChemGenex Presents Updated Analysis at ASH on OMAPRO�?�in CML Patients who Failed Two or Three Approved TKI Drugs

06 / 12 / 2010

�?� New analysis of clinical data indicates that OMAPROTM could offer a new treatment approach for CML Patients who fail to respond to TKI therapy �?� OMAPROTM induced durable major cytogenetic responses in 33% of chronic phase patients who failed currently approved drugs

> Read More

EUTHYMICS BIOSCIENCE, INC. NAMES BIOTECH EXECUTIVE TIMOTHY J. BARBERICH TO BOARD OF DIRECTORS

04 / 11 / 2010

Former Sepracor Founder and CEO Brings a History of Experience and Success in Drug Development and Commercialization

> Read More

ChemGenex Announces Convertible Note Issue and Welcomes Cephalon, Inc. as a Substantial Investor

22 / 10 / 2010

�?� Substantial Shareholders Sign Option Agreements with Subsidiary of Cephalon, Inc over 19.9% of ChemGenex Shares at A$0.70 per Share

> Read More

ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO:

13 / 07 / 2010

�?� Company will submit new NDA in CML patients who have failed multiple TKIs �?� Investor Teleconference to be held today - Wednesday 14th July 10.30am AEST /Tuesday 13th July 5.30

> Read More

Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences

13 / 07 / 2010

Women�??s Sexual Health Research on Podium at 2010 Joint ICS/IUGA Meeting

> Read More

 
Displaying records 1-25 of 43